1832 Asset Management L.P. Acquires New Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• 1832 Asset Management L.P. acquired a position in Alnylam Pharmaceuticals, purchasing 144,045 shares valued at approximately $38.9 million, representing 0.11% ownership in the company.
• Alnylam Pharmaceuticals reported a positive earnings surprise of $0.32 per share for the last quarter, exceeding analysts' expectations by $0.86, with revenue of $773.69 million, marking a 17.3% year-over-year increase.
• Several analysts have raised their price targets for Alnylam stock, with UBS Group increasing its target from $403 to $550 and a consensus rating of "Moderate Buy" among analysts.

1832 Asset Management L.P. bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 144,045 shares of the biopharmaceutical company's stock, valued at approximately $38,895,000. 1832 Asset Management L.P. owned approximately 0.11% of Alnylam Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Kaufman Rossin Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $351,000. Price T Rowe Associates Inc. MD increased its position in shares of Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after purchasing an additional 185,783 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock worth $1,192,988,000 after purchasing an additional 33,696 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. increased its position in shares of Alnylam Pharmaceuticals by 2.7% during the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 22,763 shares of the biopharmaceutical company's stock worth $6,146,000 after purchasing an additional 609 shares during the last quarter. Finally, Groupama Asset Managment increased its position in shares of Alnylam Pharmaceuticals by 0.8% during the 1st quarter. Groupama Asset Managment now owns 1,540,139 shares of the biopharmaceutical company's stock worth $415,868,000 after purchasing an additional 11,689 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Insiders Place Their Bets

In other news, EVP Jeffrey V. Poulton sold 2,274 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $1,030,735.98. Following the transaction, the executive vice president owned 50,121 shares in the company, valued at $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael W. Bonney sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the sale, the director owned 16,804 shares in the company, valued at $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 108,531 shares of company stock valued at $41,087,238. 1.20% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded up $2.98 on Wednesday, hitting $454.18. 880,422 shares of the company's stock were exchanged, compared to its average volume of 961,385. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $469.81. The stock has a market cap of $59.53 billion, a P/E ratio of -183.88 and a beta of 0.25. The company has a 50 day moving average of $366.19 and a 200 day moving average of $299.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The firm had revenue of $773,689 billion during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business's quarterly revenue was up 17.3% on a year-over-year basis. During the same period last year, the company earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ALNY shares. Needham & Company LLC boosted their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Oppenheimer raised Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price on the stock in a report on Monday, August 4th. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They set an "outperform" rating and a $370.00 target price on the stock. Citigroup boosted their target price on Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the stock a "buy" rating in a report on Friday, July 11th. Finally, Barclays upped their price objective on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $405.33.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.